Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of TAK-123 IV in Japanese healthy adult males
jRCT2080224939Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium phenylacetate + sodium benzoate, sponsored by Takeda. Primary endpoints: Pharmacokinetics of phenylacetate and benzoate after TAK-123 IV infusion and Safety and tolerability of TAK-123. Started Nov 2019; status: completed.
02
Drugs
sodium phenylacetate + sodium benzoate
Beyond the preview
Go deeper on jRCT2080224939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224939.